ATR and familial pancreatic carcinoma: Due to the role of CHK1 in G2 arrest and, consequently, HR repair of DSB, CHK1 and ATR have been described to be targets in combination with DNA damage-inducing agents as treatment approaches for pancreatic cancers [44], [45].